Apr 23, 2019

Shaping the journey of a new life science company?

After two successful years since being founded, OnDosis is accelerating. We are now looking for a Co-Pilot to the CEO, a position which will be critical in order to drive the company towards our ambition. We are looking for an energetic doer. A person that is making things happen, connecting dots and building relationships. This individual will grow with OnDosis and be part of a small but dynamic leadership team. Is it you?

OnDosis has been chosen as one of the companies selected to the Swedish IVA 100 list

The IVA (Royal Swedish Academy of Engineering Sciences) is an independent academy whose mission is “...to promote the engineering and economic sciences and the advancement of business and industry for the benefit of society”. IVA’s list brings together research that can form the basis of innovation in the form of new companies, new products and services, business development or other form of benefit.

Grünenthal and OnDosis team up for individualised dosing of oral drugs in pain management to increase patient safety

Life science startup OnDosis signs its first global development and licensing agreement for their innovative technology. Grünenthal expands its portfolio with an innovative technology for individualised dosing.

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.

Introducing OnDosis, a new life science company

Based on innovative technology developed by AstraZeneca, OnDosis is a new, Gothenburg-based, life science company with the mission to simplify dosing and enable personalised administration of medicines by connecting medicines, devices and digital health to benefit patients. AstraZeneca and GU Ventures have founded OnDosis together with entrepreneurial CEO, Martin Olovsson.